S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:BIVI

BioVie (BIVI) Stock Price, News & Analysis

$0.53
-0.01 (-1.86%)
(As of 03/28/2024 ET)
Today's Range
$0.51
$0.54
50-Day Range
$0.53
$1.89
52-Week Range
$0.48
$8.94
Volume
773,520 shs
Average Volume
2.52 million shs
Market Capitalization
$21.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

BioVie MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,413.4% Upside
$8.00 Price Target
Short Interest
Healthy
3.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of BioVie in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.33 out of 5 stars

Medical Sector

766th out of 938 stocks

Pharmaceutical Preparations Industry

347th out of 423 stocks

BIVI stock logo

About BioVie Stock (NASDAQ:BIVI)

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

BIVI Stock Price History

BIVI Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
BIVI Oct 2024 1.500 put
BIVI Jul 2024 3.500 put
BIVI Apr 2024 5.000 put
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
BioVie Inc. Announces Closing of Public Offering
BIVI Apr 2024 1.500 put
BIVI Oct 2024 0.500 put
Why BioVie (BIVI) Shares Are Down 40%
See More Headlines
Receive BIVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BIVI
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$11.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,413.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-50,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.42 per share

Miscellaneous

Free Float
38,009,000
Market Cap
$21.10 million
Optionable
Optionable
Beta
0.90
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Cuong Viet Do M.B.A. (Age 58)
    President, CEO & Director
    Comp: $1.08M
  • Ms. Joanne Wendy Kim CPA (Age 69)
    CFO, Treasurer & Corporate Secretary
    Comp: $397.38k
  • Dr. Joseph M. Palumbo M.D. (Age 64)
    Executive VP of R&D and Chief Medical Officer
    Comp: $722k
  • Mr. Clarence N. Ahlem (Age 69)
    Senior Vice President of Operations
  • Dr. Penelope Markham Ph.D. (Age 58)
    Senior Vice President of Liver Disease Program
  • Ms. Denise Smith
    Senior Vice President of Manufacturing & Development
  • Dr. Christopher L. Reading Ph.D. (Age 76)
    Senior Vice President of Alzheimer's Disease Program
  • Ms. Sarah Overton Hoit (Age 56)
    Chief Social Impact Officer

BIVI Stock Analysis - Frequently Asked Questions

Should I buy or sell BioVie stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioVie in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BIVI shares.
View BIVI analyst ratings
or view top-rated stocks.

What is BioVie's stock price target for 2024?

2 brokerages have issued 12 month price objectives for BioVie's shares. Their BIVI share price targets range from $5.00 to $11.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 1,413.4% from the stock's current price.
View analysts price targets for BIVI
or view top-rated stocks among Wall Street analysts.

How have BIVI shares performed in 2024?

BioVie's stock was trading at $1.26 at the beginning of 2024. Since then, BIVI shares have decreased by 58.0% and is now trading at $0.5286.
View the best growth stocks for 2024 here
.

Are investors shorting BioVie?

BioVie saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,540,000 shares, an increase of 51.0% from the February 29th total of 1,020,000 shares. Based on an average daily trading volume, of 2,360,000 shares, the days-to-cover ratio is currently 0.7 days.
View BioVie's Short Interest
.

When is BioVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our BIVI earnings forecast
.

How were BioVie's earnings last quarter?

BioVie Inc. (NASDAQ:BIVI) issued its earnings results on Monday, February, 12th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.10.

Who are BioVie's major shareholders?

BioVie's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.93%), Vanguard Group Inc. (0.88%), Northern Trust Corp (0.29%), Charles Schwab Investment Management Inc. (0.08%), Virtu Financial LLC (0.06%) and Envestnet Asset Management Inc. (0.06%). Insiders that own company stock include Cuong V Do, Joanne Wendy Kim, Richard J Berman and Steve Gorlin.
View institutional ownership trends
.

How do I buy shares of BioVie?

Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BIVI) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners